Valproic acid pathway: pharmacokinetics and pharmacodynamics.
Valproic acid pathway: pharmacokinetics and pharmacodynamics.
复制标题
DOI：
10.1097/fpc.0b013e32835ea0b2
复制
发表时间：
2013-04
影响因子：
2.6
通讯作者：
Klein TE
中科院分区：
文献类型：
--
作者：
Ghodke-Puranik Y;Thorn CF;Lamba JK;Leeder JS;Song W;Birnbaum AK;Altman RB;Klein TE
丙戊酸(VPA)是一种来源于天然丙戊酸的支链短链脂肪酸。VPA主要用于治疗癫痫和癫痫发作，但也用于偏头痛、躁郁症、情绪障碍、焦虑和精神障碍[1]。最近的工作探索了它作为组蛋白脱乙酰酶(HDAC)抑制剂的作用在癌症、艾滋病毒治疗和神经退行性疾病中的应用[2]。VPA因其多种作用机制和可接受的安全性而被广泛用于儿童癫痫[3]。VPA的剂量要求是高度可变的(成人的平均剂量相差10倍)[4]，与其他药物的相互作用也很常见(讨论如下)。治疗药物监测是常用的，尽管药物的临床和毒性作用被认为与血清总浓度的相关性很差[3]。
Valproic acid (VPA) is a branched short-chain fatty acid derived from naturally occurring valeric acid. VPA is used primarily in the treatment of epilepsy and seizures, but is also used in migraine, bipolar, mood, anxiety, and psychiatric disorders [1]. Recent work has explored its use as an adjuvant agent in cancer, HIV therapy, and neurodegenerative disease because of its action as histone deacetylase (HDAC) inhibitor [2].VPA is widely used in pediatric epilepsy because of its multiple mechanisms of action and acceptable safety profile [3]. The dose requirements for VPA are highly variable (10-fold differences in mean dose in adults)[4] and interactions with other drugs are common (discussed below). Therapeutic drug monitoring is commonly used, although both the clinical and toxic effects of the drug are considered to be poorly correlated with total serum concentrations [3].